Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader
in life science research and clinical diagnostic products, today
announced financial results for the fourth quarter and full year
ended December 31, 2022.
Fourth-quarter 2022 net sales were $730.3 million, a decrease of
0.3 percent compared to $732.8 million reported for the fourth
quarter of 2021. COVID-related revenue was approximately $13
million in the fourth quarter of 2022 versus approximately $46
million reported in the year-ago period. On a currency-neutral
basis, quarterly sales increased 5.8 percent compared to the same
period in 2021. Fourth-quarter 2022 revenue increased 10.6 percent
on a currency-neutral basis when excluding COVID-related sales.
Fourth-quarter 2022 gross margin was 54.4 percent compared to
54.6 percent for the fourth quarter of 2021.
Life Science segment net sales for the fourth quarter were
$359.7 million, an increase of 10.1 percent compared to the same
period in 2021. On a currency-neutral basis, the segment sales
increased 16.4 percent compared to the same quarter in 2021. When
also excluding COVID-related sales, Life Science revenue increased
28.1 percent, and were primarily driven by Droplet Digital™ PCR,
process chromatography, Western blotting, and qPCR products.
Clinical Diagnostics segment net sales for the fourth quarter
were $369.6 million, a decrease of 8.7 percent compared to the same
period in 2021. On a currency-neutral basis, net sales decreased
2.9 percent versus the same quarter last year. Excluding
COVID-related sales, Clinical Diagnostics revenue decreased 1.9
percent from the year-ago period, on a currency-neutral basis. The
decrease was primarily driven by continuing supply chain
constraints, which impacted instrument placements and sales of
related consumables.
Income from operations for the fourth quarter of 2022 was $118.7
million versus $108.9 million during the same quarter last
year.
Net income for the fourth quarter of 2022 was $827.7 million, or
$27.78 per share, on a diluted basis, versus a net loss of $1,572.2
million, or $52.54 per share, on a diluted basis, during the same
period in 2021. Net income (loss) amounts for the fourth quarter of
2022 and 2021 were predominantly impacted by the recognition of
changes in the fair market value of equity securities related to
the holdings of the company’s investment in Sartorius AG.
The effective tax rate for the fourth quarter of 2022 was 24.2%,
compared to 22.8% for the same period in 2021. The effective tax
rate reported in Q4 of 2022 was primarily affected by an unrealized
gain in equity securities, and the tax rate reported in Q4 of 2021
was primarily affected by unrealized loss in equity securities.
“During the fourth quarter, we continued to make progress,
working through the ongoing global supply chain challenges,” said
Norman Schwartz, Bio-Rad’s President, and Chief Executive Officer.
“We also saw positive market response to new product introductions,
setting the stage for 2023.”
GAAP Results
Q4 2022
Q4 2021
Revenue (millions)
$730.3
$732.8
Gross margin
54.4%
54.6%
Operating margin
16.2%
14.9%
Net income (loss) (millions)
$827.7
$(1,572.2)
Income (loss) per diluted share
$27.78
$(52.54)
Non-GAAP Results
Q4 2022
Q4 2021
Revenue (millions)
$730.3
$732.8
Gross margin
54.9%
55.2%
Operating margin
17.4%
15.7%
Net income (millions)
$98.5
$98.5
Income per diluted share
$3.31
$3.26
A reconciliation between GAAP operating results and non-GAAP
operating results is provided following the financial statements
that are part of this press release. Non-GAAP adjustments include
amortization of purchased intangibles; acquisition-related expenses
and benefits; restructuring, impairment charges and gains and
losses from change in fair market value of equity securities and
loan receivable; gains and losses on equity-method investments;
significant litigation charges or benefits and legal costs; and
discrete income tax events and the income tax effect on these
non-GAAP adjustments.
Non-GAAP net income and non-GAAP diluted income per share
(non-GAAP EPS) are non-GAAP measures that exclude certain items
detailed later in this press release under the heading “Non-GAAP
and Currency-Neutral Reporting.”
Non-GAAP net income for the fourth quarter of 2022 was $98.5
million, or $3.31 per share, on a diluted basis, compared to $98.5
million, or $3.26 per share, on a diluted basis, during the same
period in 2021.
The non-GAAP effective tax rate for the fourth quarter of 2022
was 28.1 compared to 20.4 percent for the same period in 2021. The
higher tax rate in 2022 was driven by a geographical mix of
earnings.
The following table represents a reconciliation of Bio-Rad’s
reported net income (loss) and diluted income (loss) per share to
non-GAAP net income and non-GAAP diluted income per share for the
three and twelve months ended December 31, 2022, and 2021:
In thousands, except per share data
Three Months Ended December
31, 2022
Three Months Ended December
31, 2021
Year Ended December 31,
2022
Year Ended December 31,
2021
GAAP net income (loss)
$ 827,734
$ (1,572,163)
$ (3,627,535)
$ 4,254,257
Legal settlements
-
-
-
(28,619)
Amortization of purchased intangibles
6,069
6,498
24,904
27,530
Legal matters
308
874
2,374
16,375
Acquisition related benefits
(494)
-
(494)
(40)
Restructuring (benefits) costs
31
(3,510)
4,594
64,289
(Gains) losses from change in fair market
value of equity securities and loan receivable
(978,752)
2,152,505
5,193,554
(4,926,248)
Losses on equity-method investments
16,133
1,615
25,310
7,194
Other non-recurring items (2) (3)
2,454
1,909
8,600
1,909
Income tax effect of non-GAAP adjustments
(1)
225,007
(489,230)
(1,198,728)
1,064,912
Non-GAAP net income
$ 98,490
$ 98,498
$ 432,579
$ 481,559
GAAP diluted income (loss) per
share
$ 27.78
$ (52.54)
$ (121.79)
$ 140.83
Non-GAAP diluted income per
share
$ 3.31
$ 3.26
$ 14.42
$ 15.94
(1)
Excluded items identified in the
reconciliation schedule are tax effected by application of a
non-GAAP effective tax rate. The non-GAAP tax provision is adjusted
for items, the nature of which and/or tax jurisdiction requires the
application of a specific tax rate or treatment.
(2)
Incremental costs to comply with the
European Union's In Vitro Diagnostics Regulation ("IVDR") for
previously approved products.
(3)
Gain from the release of an escrow for the
sale of a division in 2020.
Full-Year 2022 Results
On a reported basis, net sales for the full year 2022 decreased
4.1 percent to $2,802.2 million compared to $2,922.5 million for
the prior year. On a currency-neutral basis, net sales grew 0.3
percent. When excluding a royalty-related legal settlement totaling
$32 million in 2021, full-year 2022 sales grew 1.5 percent on a
currency-neutral basis.
COVID-related sales for the full year were approximately $109
million, compared to $266 million in the year-ago period. Excluding
COVID-related sales and the royalty-related legal settlement of $32
million, full-year 2022 revenue increased 7.2 percent
year-over-year on a currency-neutral basis.
Full-year 2022 reported net sales for the Life Science segment
were $1,347.2 million, an increase of 2.7 percent compared to the
same period in 2021 on a currency-neutral basis and excluding the
legal settlement in 2021. Life Science revenue grew 15.2 percent on
a currency-neutral basis in 2022 versus 2021 when excluding
COVID-related sales and the legal settlement.
Full-year 2022 reported net sales for the Clinical Diagnostics
segment were $1,451.0 million, an increase of 0.4 percent compared
to the prior year on a currency-neutral basis. When excluding
COVID-related sales, full-year Clinical Diagnostics revenue grew
1.3 percent compared to 2021 on a currency-neutral basis.
Full-year 2022 gross margin was 55.9 percent, compared to 56.1
percent in 2021.
Net loss for full-year 2022 was $3,627.5 million, or $121.79 per
share, on a fully diluted basis, compared to net income of $4,254.3
million, or $140.83 per share, in 2021.
The effective tax rate for the full year of 2022 was 22.9
percent compared to 21.9 percent in 2021. The effective tax rate
reported in 2022 was primarily affected by an unrealized loss in
equity securities and the tax rate reported in 2021 was primarily
affected by unrealized gain in equity securities.
The non-GAAP effective tax rate for the full year of 2022 was
22.0 percent compared to 21.2 percent in 2021.
Non-GAAP net income for 2022 was $432.6 million, or $14.42 per
share, compared to $481.6 million, or $15.94 per share in 2021.
“While 2022 financial results were largely in line with our
expectations, it is also important to recognize the measurable
progress achieved on our operational initiatives,” said Mr.
Schwartz. “Looking forward to 2023, we remain focused on leveraging
our operational scale, operational improvements, and continued
innovation. Our markets are strong and have largely recovered from
the pandemic, giving us a positive outlook for growth. We extend
sincere thanks to our employees across the globe for their ongoing
commitment to supporting our customers as we continue our
transformation and growth.”
Full-Year 2022 Highlights
- Full-year 2022 reported net sales were $2,802.2 million
compared to $2,922.5 million for the full year of 2021. Excluding
COVID-related sales and a royalty-related legal settlement in 2021,
full-year 2022 revenue increased 7.2 percent year-over-year on a
currency neutral basis.
- Full-year 2022 reported net loss was $3,627.5 million, or
$121.79 per share, on a fully diluted basis, compared to net income
of $4,254.3 million, or $140.83 per share, in 2021.
- In early 2022, during its Investor Day event, Bio-Rad’s
management outlined a three-phased approach to the company’s
continued transformation, including standardizing global
operations, improving operational performance, and accelerating
growth.
- During 2022, the company continued to expand its portfolio of
qPCR instruments, including the CFX Duet Real-Time PCR and CFX Opus
Deepwell Systems, which provide greater workflow flexibility.
- In June, the company introduced its CHT prepacked Foresight Pro
Columns to support downstream process-scale chromatography
applications in biological drug development and production.
- During the second quarter, Bio-Rad introduced its Genesis Cell
Isolation System, utilizing Celselect Slides™ technology offering
an improved method for the enrichment and enumeration of
circulating tumor cells (CTCs) in liquid biopsies.
- In August, Bio-Rad released new, proprietary tools for
discovery and drug development and expanded its libraries of dyes
and antibodies (StarBright™ Dyes and Pioneer™ Antibody Discovery
Platform).
- In September, as part of the company’s molecular diagnostics
strategy, Bio-Rad acquired an innovative, “sample-to-result” rapid
PCR technology from Curiosity Diagnostics™ for syndromic infectious
disease testing.
- During the third quarter, the company introduced its QX600™
Droplet Digital PCR platform to enable new, advanced multiplexing
applications.
- During the fourth quarter, Bio-Rad secured an exclusive
licensing agreement with NuProbe™ USA, a genomics and molecular
diagnostics company, to develop next-generation, highly multiplexed
digital PCR assays for oncology applications.
- Throughout 2022, Bio-Rad installed its IH-500™ immunohematology
systems across South Africa’s National Blood Services (SANBS)
network addressing the country’s need for high-quality blood
products and services.
2023 Financial Outlook
For the full year 2023, the company anticipates non-GAAP,
currency-neutral revenue growth of approximately 6.0 to 7.0 percent
and an estimated non-GAAP operating margin of approximately 19.5
percent. Bio-Rad’s management will discuss this outlook in greater
detail during the fourth-quarter and full-year 2022 financial
results conference call.
Conference Call and Webcast
Bio-Rad’s management will review the results for the fourth
quarter and full year ended December 31, 2022, in a conference call
scheduled for 2 PM Pacific Time (5 PM Eastern Time) on February 16,
2023. To participate, call 844-200-6205 within the U.S. or +1
929-526-1599 outside the U.S., access code: 143970. A live webcast
of the conference call will be accessible in the "Investor
Relations" section of the company’s website under "Events &
Presentations" at investors.bio-rad.com. A replay of the webcast
will be available for up to a year.
Use of Non-GAAP and Currency-Neutral Reporting
In addition to the financial measures prepared in accordance
with generally accepted accounting principles (GAAP), we use
certain non-GAAP financial measures, including non-GAAP net income
and non-GAAP EPS, which exclude amortization of acquisition-related
intangible assets, certain acquisition-related expenses and
benefits, restructuring charges, asset impairment charges, gains
and losses from change in fair market value of equity securities
and loan receivable, gains and losses on equity-method investments,
and significant legal-related charges or benefits and associated
legal costs. Non-GAAP net income and non-GAAP EPS also exclude
certain other gains and losses that are either isolated or cannot
be expected to occur again with any predictability, tax
provisions/benefits related to the previous items, and significant
discrete tax events. We exclude the above items because they are
outside of our normal operations and/or, in certain cases, are
difficult to forecast accurately for future periods.
We utilize a number of different financial measures, both GAAP
and non-GAAP, in analyzing and assessing the overall performance of
our business, in making operating decisions, forecasting and
planning for future periods, and determining payments under
compensation programs. We consider the use of the non-GAAP measures
to be helpful in assessing the performance of the ongoing operation
of our business. We believe that disclosing non-GAAP financial
measures provides useful supplemental data that, while not a
substitute for financial measures prepared in accordance with GAAP,
allows for greater transparency in the review of our financial and
operational performance. We also believe that disclosing non-GAAP
financial measures provides useful information to investors and
others in understanding and evaluating our operating results and
future prospects in the same manner as management and in comparing
financial results across accounting periods and to those of peer
companies. More specifically, management adjusts for the excluded
items for the following reasons:
Amortization of purchased intangible assets: we do not acquire
businesses and assets on a predictable cycle. The amount of
purchase price allocated to purchased intangible assets and the
term of amortization can vary significantly and are unique to each
acquisition or purchase. We believe that excluding amortization of
purchased intangible assets allows the users of our financial
statements to better review and understand the historic and current
results of our operations, and also facilitates comparisons to peer
companies.
Acquisition-related expenses and benefits: we incur expenses or
benefits with respect to certain items associated with our
acquisitions, such as transaction costs, professional fees for
assistance with the transaction; valuation or integration costs;
changes in the fair value of contingent consideration, gain or loss
on settlement of pre-existing relationships with the acquired
entity; or adjustments to purchase price. We exclude such expenses
or benefits as they are related to acquisitions and have no direct
correlation to the operation of our ongoing business.
Restructuring, impairment charges, and gains and losses from
change in fair market value of equity securities and loan
receivable, and gains and losses on equity-method investments: we
incur restructuring and impairment charges on individual or groups
of employed assets and charges and benefits arising from gains and
losses from change in fair market value of equity securities and
loan receivable, and gains and losses (including impairments) on
equity-method investments, which arise from unforeseen
circumstances and/or often occur outside of the ordinary course of
our on-going business. Although these events are reflected in our
GAAP financials, these unique transactions may limit the
comparability of our ongoing operations with prior and future
periods.
Significant litigation charges or benefits and legal costs: we
may incur charges or benefits as well as legal costs in connection
with litigation and other contingencies unrelated to our core
operations. We exclude these charges or benefits, when significant,
as well as legal costs associated with significant legal matters
because we do not believe they are reflective of ongoing business
and operating results.
Income tax expense: we estimate the tax effect of the excluded
items identified above to determine a non-GAAP annual effective tax
rate applied to the pretax amount in order to calculate the
non-GAAP provision for income taxes. We also adjust for items for
which the nature and/or tax jurisdiction requires the application
of a specific tax rate or treatment.
From time to time in the future, there may be other items
excluded if we believe that doing so is consistent with the goal of
providing useful information to investors and management.
Percentage sales growth in currency-neutral amounts are
calculated by translating prior period sales in each local currency
using the current period’s monthly average foreign exchange rates
for that currency and comparing that to current period sales.
There are limitations in using non-GAAP financial measures
because the non-GAAP financial measures are not prepared in
accordance with generally accepted accounting principles and may be
different from non-GAAP financial measures used by other companies.
The non-GAAP financial measures are limited in value because they
exclude certain items that may have a material impact on our
reported financial results. The presentation of this additional
information is not meant to be considered in isolation or as a
substitute for the directly comparable financial measures prepared
in accordance with GAAP in the United States. Investors should
review the reconciliation of the non-GAAP financial measures to
their most directly comparable GAAP financial measures as provided
in the tables accompanying this press release.
BIO-RAD, CELSELECT SLIDES, DROPLET DIGITAL, IH-500, PIONEER,
QX600 and STARBRIGHT are trademarks of Bio-Rad Laboratories, Inc.
or Bio-Rad Medical Diagnostics GmbH in certain jurisdictions.
NUPROBE is a trademark of NuProbe USA, Inc.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global
leader in developing, manufacturing, and marketing a broad range of
innovative products for the life science research and clinical
diagnostic markets. With 70 years of focus on quality and customer
service, our products advance the scientific discovery process and
improve healthcare. Our customers are universities, research
institutions, hospitals, biotechnology and pharmaceutical
companies, as well as public health and commercial laboratories
including food safety and environmental quality testing facilities.
Based in Hercules, California, Bio-Rad has a global network of
operations with approximately 8,300 employees worldwide and $2.8
billion in revenues in 2022. For more information, please visit
bio-rad.com.
Forward-Looking Statements
This release may be deemed to contain certain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include,
without limitation, statements we make regarding estimated future
financial performance or results; in 2023, remaining focused on
leveraging our operational scale, operational improvements, and
continued innovation; continuing our transformation and growth; and
for the full-year 2023, anticipating non-GAAP currency-neutral
revenue growth of approximately 6.0 to 7.0 percent, and an
estimated non-GAAP operating margin of approximately 19.5 percent.
Forward-looking statements generally can be identified by the use
of forward-looking terminology such as, "anticipate," "estimate,"
"expect," "continue," "believe," "will," "project," "assume,"
"may," "intend," or similar expressions or the negative of those
terms or expressions, although not all forward-looking statements
contain these words. Such statements involve risks and
uncertainties, which could cause actual results to vary materially
from those expressed in or indicated by the forward-looking
statements. These risks and uncertainties include the duration,
severity and impact of the COVID-19 pandemic, supply chain issues,
global economic conditions, foreign currency exchange fluctuations,
our ability to develop and market new or improved products, our
ability to compete effectively, reductions in government funding or
capital spending of our customers, international legal and
regulatory risks, product quality and liability issues, our ability
to integrate acquired companies, products or technologies into our
company successfully, changes in the healthcare industry, and
natural disasters and other catastrophic events beyond our control.
For further information regarding the Company's risks and
uncertainties, please refer to the "Risk Factors" and "Management’s
Discussion and Analysis of Financial Condition and Results of
Operations" in the Company's public reports filed with the
Securities and Exchange Commission (the "SEC"), including the
Company's Annual Report on Form 10-K for the fiscal year ended
December 31, 2021, its Quarterly Report on Form 10-Q for the
quarter ended September 30, 2022, and its Annual Report on Form
10-K for the fiscal year ended December 31, 2022 to be filed with
the SEC. The Company cautions you not to place undue reliance on
forward-looking statements, which reflect an analysis only and
speak only as of the date hereof. Bio-Rad Laboratories, Inc.
disclaims any obligation to update these forward-looking
statements.
Bio-Rad Laboratories,
Inc.
Condensed Consolidated
Statements of Income (Loss)
(In thousands, except per share
data)
(Unaudited)
Three Months Ended
Year Ended
December 31,
December 31,
2022
2021
2022
2021
Net sales
$
730,288
$
732,769
$
2,802,249
$
2,922,545
Cost of goods sold
333,191
332,829
1,234,919
1,284,449
Gross profit
397,097
399,940
1,567,330
1,638,096
Selling, general and administrative expense
212,227
224,111
827,825
877,122
Research and development expense
66,200
66,917
256,889
260,638
Income from operations
118,670
108,912
482,616
500,336
Interest expense
11,683
364
38,114
1,551
Foreign currency exchange (gains) losses, net
(3,338
)
2,211
(205
)
2,753
(Gains) losses from change in fair market value of equity
securities and loan receivable
(978,752
)
2,152,505
5,193,554
(4,926,248
)
Other (income), net
(2,205
)
(10,043
)
(44,574
)
(26,775
)
Income (loss) before income taxes
1,091,282
(2,036,125
)
(4,704,273
)
5,449,055
(Provision for) benefit from income taxes
(263,548
)
463,962
1,076,738
(1,194,798
)
Net income (loss)
$
827,734
$
(1,572,163
)
$
(3,627,535
)
$
4,254,257
Basic earnings (loss) per share: Net income (loss) per basic
share
$
27.89
$
(52.54
)
$
(121.79
)
$
142.61
Weighted average common shares - basic
29,683
29,922
29,785
29,831
Diluted earnings (loss) per share: Net income (loss) per
diluted share
$
27.78
$
(52.54
)
$
(121.79
)
$
140.83
Weighted average common shares - diluted
29,792
29,922
29,785
30,208
Note: As a result of the net loss for the
nine months ended December 31, 2022, and for the three months ended
December 31, 2021, all potentially issuable common shares have been
excluded from the diluted shares used in the computation of
earnings per share as their effect was anti-dilutive.
Bio-Rad Laboratories, Inc. Condensed Consolidated Balance
Sheets (In thousands)
December 31,
December 31,
2022
2021
(Unaudited) Current assets: Cash and cash equivalents
$
434,215
$
470,783
Short-term investments
1,362,017
404,695
Accounts receivable, net
494,645
423,537
Inventories, net
719,316
572,239
Other current assets
147,783
119,225
Total current assets
3,157,976
1,990,479
Property, plant and equipment, net
498,612
511,639
Operating lease right-of-use assets
180,952
204,798
Goodwill, net
406,488
347,343
Purchased intangibles, net
332,147
253,939
Other investments
8,830,892
14,387,006
Other assets
94,599
104,189
Total assets
$
13,501,666
$
17,799,393
Current liabilities: Accounts payable, accrued payroll and
employee benefits
$
329,831
$
418,927
Current maturities of long-term debt
465
489
Income and other taxes payable
32,428
46,299
Other current liabilities
205,984
215,223
Total current liabilities
568,708
680,938
Long-term debt, net of current maturities
1,197,716
10,514
Other long-term liabilities
2,119,990
3,422,705
Total liabilities
3,886,414
4,114,157
Total stockholders' equity
9,615,252
13,685,236
Total liabilities and stockholders' equity
$
13,501,666
$
17,799,393
Bio-Rad Laboratories, Inc. Condensed Consolidated
Statements of Cash Flows (In thousands) (Unaudited)
Year Ended December 31,
2022
2021
Cash flows from operating activities: Cash received from
customers
$
2,699,401
$
2,886,489
Cash paid to suppliers and employees
(2,408,043
)
(2,127,939
)
Interest paid, net
(24,435
)
(2,251
)
Income tax payments, net
(158,259
)
(134,683
)
Other operating activities
85,783
47,848
Net cash provided by operating activities
194,447
669,464
Cash flows from investing activities: Payments for
acquisitions
(100,746
)
(125,516
)
Payments for purchases of marketable securities and investments
(2,060,238
)
(851,627
)
Proceeds from sales and maturities of marketable securities and
investments
1,066,027
766,896
Payments for investment in loan instrument
-
(453,440
)
Other investing activities
(112,636
)
(133,694
)
Net cash used in investing activities
(1,207,593
)
(797,381
)
Cash flows from financing activities: Proceeds from issuance
of Notes, net of debt financing costs
1,186,220
-
Payments on long-term borrowings
(510
)
(3,020
)
Other financing activities
(212,134
)
(52,409
)
Net cash provided by (used in) financing activities
973,576
(55,429
)
Effect of foreign exchange rate changes on cash
2,981
(12,636
)
Net decrease in cash, cash equivalents and restricted cash
(36,589
)
(195,982
)
Cash, cash equivalents and restricted cash at beginning of year
471,133
667,115
Cash, cash equivalents and restricted cash at end of year
$
434,544
$
471,133
Reconciliation of net income (loss) to net cash
provided by operating activities: Net income (loss)
$
(3,627,535
)
$
4,254,257
Adjustments to reconcile net income (loss) to net cash provided by
operating activities: Depreciation and amortization
137,296
137,592
Reduction in the carrying amount of right-of-use assets
39,924
39,264
(Gains) losses from change in fair market value of equity
securities and loan receivable
5,193,554
(4,926,248
)
Changes in working capital
(407,038
)
13,230
Other
(1,141,754
)
1,151,369
Net cash provided by operating activities
$
194,447
$
669,464
Bio-Rad Laboratories,
Inc.
Reconciliation of GAAP
financial measures to non-GAAP financial measures
(In thousands, except per share
data)
(Unaudited)
In addition to the financial measures
prepared in accordance with generally accepted accounting
principles (GAAP), we use certain non-GAAP financial measures,
including non-GAAP net income and non-GAAP diluted income per share
(non-GAAP EPS), which exclude amortization of acquisition-related
intangible assets; certain acquisition-related expenses and
benefits; restructuring charges; asset impairment charges; gains
and losses from change in fair market value of equity securities
and loan receivable; gains and losses on equity-method investments;
and significant legal-related charges or benefits and associated
legal costs. Non-GAAP net income and non-GAAP EPS also exclude
certain other gains and losses that are either isolated or cannot
be expected to occur again with any predictability, tax
provisions/benefits related to the previous items, and significant
discrete tax events. We exclude the above items because they are
outside of our normal operations and/or, in certain cases, are
difficult to forecast accurately for future periods.
We utilize a number of different financial
measures, both GAAP and non-GAAP, in analyzing and assessing the
overall performance of our business, in making operating decisions,
forecasting and planning for future periods, and determining
payments under compensation programs. We consider the use of the
non-GAAP measures to be helpful in assessing the performance of the
ongoing operation of our business. We believe that disclosing
non-GAAP financial measures provides useful supplemental data that,
while not a substitute for financial measures prepared in
accordance with GAAP, allows for greater transparency in the review
of our financial and operational performance. We also believe that
disclosing non-GAAP financial measures provides useful information
to investors and others in understanding and evaluating our
operating results and future prospects in the same manner as
management and in comparing financial results across accounting
periods and to those of peer companies.
Three Months Ended Three Months Ended Year
Ended Year Ended December 31, % of
December 31, % of December 31, % of
December 31, % of
2022
revenue
2021
revenue
2022
revenue
2021
revenue GAAP net sales
$
730,288
$
732,769
$
2,802,249
$
2,922,545
Legal settlements
-
-
-
(31,843
)
Non-GAAP net sales
$
730,288
$
732,769
$
2,802,249
$
2,890,702
GAAP cost of goods sold
$
333,191
$
332,829
$
1,234,919
$
1,284,449
Amortization of purchased intangibles
(4,356
)
(4,659
)
(17,697
)
(18,562
)
Legal settlements
-
-
-
(3,535
)
Restructuring benefits (costs)
229
112
(1,059
)
(25,129
)
Other non-recurring items (2)
-
(274
)
-
(274
)
Non-GAAP cost of goods sold
$
329,064
$
328,008
$
1,216,163
$
1,236,949
GAAP gross profit
$
397,097
54.4
%
$
399,940
54.6
%
$
1,567,330
55.9
%
$
1,638,096
56.1
%
Amortization of purchased intangibles
4,356
4,659
17,697
18,562
Legal settlements
-
-
-
(28,308
)
Restructuring (benefits) costs
(229
)
(112
)
1,059
25,129
Other non-recurring items (2)
-
274
-
274
Non-GAAP gross profit
$
401,224
54.9
%
$
404,761
55.2
%
$
1,586,086
56.6
%
$
1,653,753
57.2
%
GAAP selling, general and administrative expense
$
212,227
$
224,111
$
827,825
$
877,122
Amortization of purchased intangibles
(1,713
)
(1,839
)
(7,207
)
(8,968
)
Legal matters
(308
)
(874
)
(2,374
)
(16,375
)
Acquisition related benefits (costs)
494
-
494
40
Restructuring benefits (costs)
(419
)
1,367
(3,364
)
(26,140
)
Other non-recurring items (2)
(2,454
)
(1,635
)
(9,960
)
(1,635
)
Non-GAAP selling, general and administrative expense
$
207,827
$
221,130
$
805,414
$
824,044
GAAP research and development expense
$
66,200
$
66,917
$
256,889
$
260,638
Restructuring benefits (costs)
159
2,031
(171
)
(13,020
)
Non-GAAP research and development expense
$
66,359
$
68,948
$
256,718
$
247,618
GAAP income from operations
$
118,670
16.2
%
$
108,912
14.9
%
$
482,616
17.2
%
$
500,336
17.1
%
Legal settlements
-
-
-
(28,308
)
Amortization of purchased intangibles
6,069
6,498
24,904
27,530
Legal matters
308
-
-
874
2,374
16,375
Acquisition related (benefits) costs
(494
)
-
(494
)
(40
)
Restructuring (benefits) costs
31
(3,510
)
4,594
64,289
Other non-recurring items (2)
2,454
1,909
9,960
1,909
Non-GAAP income from operations
$
127,038
17.4
%
$
114,683
15.7
%
$
523,954
18.7
%
$
582,091
20.1
%
GAAP (gains) losses from change in fair market value of
equity securities and loan receivable
$
(978,752
)
$
2,152,505
$
5,193,554
$
(4,926,248
)
Gains (losses) from change in fair market value of equity
securities and loan receivable
978,752
(2,152,505
)
(5,193,554
)
4,926,248
Non-GAAP (gains) losses from change in fair market value of
equity securities and loan receivable
$
-
$
-
$
-
$
-
GAAP other (income) expense, net
$
(2,205
)
$
(10,043
)
$
(44,574
)
$
(26,775
)
Gains (losses) on equity-method investments
(16,133
)
(1,615
)
(25,310
)
(7,194
)
Legal settlements
-
-
-
311
Other non-recurring items (3)
-
-
1,360
-
Non-GAAP other (income) expense, net
$
(18,338
)
$
(11,658
)
$
(68,524
)
$
(33,658
)
GAAP income (loss) before income taxes
$
1,091,282
$
(2,036,125
)
$
(4,704,273
)
$
5,449,055
Legal settlements
-
-
-
(28,619
)
Amortization of purchased intangibles
6,069
6,498
24,904
27,530
Legal matters
308
874
2,374
16,375
Acquisition related (benefits) costs
(494
)
-
(494
)
(40
)
Restructuring (benefits) costs
31
(3,510
)
4,594
64,289
(Gains) losses from change in fair market value of equity
securities and loan receivable
(978,752
)
2,152,505
5,193,554
(4,926,248
)
(Gains) losses on equity-method investments
16,133
1,615
25,310
7,194
Other non-recurring items (2) (3)
2,454
1,909
8,600
1,909
Non-GAAP income before income taxes
$
137,031
$
123,766
$
554,569
$
611,445
GAAP (provision for) benefit from income taxes
$
(263,548
)
$
463,962
$
1,076,738
$
(1,194,798
)
Income tax effect of non-GAAP adjustments (1)
225,007
(489,230
)
(1,198,728
)
1,064,912
Non-GAAP provision for income taxes
$
(38,541
)
$
(25,268
)
$
(121,990
)
$
(129,886
)
GAAP net income (loss)
$
827,734
113.3
%
$
(1,572,163
)
-214.6
%
$
(3,627,535
)
-129.5
%
$
4,254,257
145.6
%
Legal settlements
-
-
-
(28,619
)
Amortization of purchased intangibles
6,069
6,498
24,904
27,530
Legal matters
308
874
2,374
16,375
Acquisition related (benefits) costs
(494
)
-
(494
)
(40
)
Restructuring (benefits) costs
31
(3,510
)
4,594
64,289
(Gains) losses from change in fair market value of equity
securities and loan receivable
(978,752
)
2,152,505
5,193,554
(4,926,248
)
(Gains) losses on equity-method investments
16,133
1,615
25,310
7,194
Other non-recurring items (2) (3)
2,454
1,909
8,600
1,909
Income tax effect of non-GAAP adjustments (1)
225,007
(489,230
)
(1,198,728
)
1,064,912
Non-GAAP net income
$
98,490
13.5
%
$
98,498
13.4
%
$
432,579
15.4
%
$
481,559
16.7
%
GAAP diluted income (loss) per share
$
27.78
$
(52.54
)
$
(121.79
)
$
140.83
Legal settlements
-
-
-
(0.95
)
Amortization of purchased intangibles
0.20
0.22
0.83
0.91
Legal matters
0.01
0.03
0.08
0.54
Acquisition related (benefits) costs
(0.02
)
-
(0.02
)
-
Restructuring (benefits) costs
-
(0.12
)
0.15
2.13
(Gains) losses from change in fair market value of equity
securities and loan receivable
(32.85
)
71.24
173.12
(163.08
)
(Gains) losses on equity-method investments
0.54
0.05
0.84
0.24
Other non-recurring items (2) (3)
0.08
0.06
0.29
0.06
Income tax effect of non-GAAP adjustments (1)
7.57
(16.18
)
(39.95
)
35.26
Add back anti-dilutive shares
-
0.50
0.87
-
Non-GAAP diluted income per share
$
3.31
$
3.26
$
14.42
$
15.94
GAAP diluted weighted average shares used in per share
calculation
29,792
29,922
29,785
30,208
Shares included in non-GAAP net income per share, but excluded from
GAAP net loss per share as they would have been anti-dilutive
-
291
215
-
Non-GAAP diluted weighted average shares used in per share
calculation
29,792
30,213
30,000
30,208
Reconciliation of Net income (loss) to adjusted
EBITDA: GAAP net income (loss)
$
827,734
113.3
%
$
(1,572,163
)
-214.6
%
$
(3,627,535
)
-129.5
%
$
4,254,257
145.6
%
Interest expense
11,683
364
38,114
1,551
(Benefit from) provision for income taxes
263,548
(463,962
)
(1,076,738
)
1,194,798
Depreciation and amortization
35,514
35,004
137,296
137,592
Foreign currency exchange (gains) losses, net
(3,338
)
2,211
(205
)
2,753
Other (income), net
(2,205
)
(10,043
)
(44,574
)
(26,775
)
(Gains) losses from change in fair market value of equity
securities and loan receivable
(978,752
)
2,152,505
5,193,554
(4,926,248
)
Dividend from Sartorius AG
-
-
31,586
18,991
Legal settlements (4)
-
-
-
(28,308
)
Legal matters
308
874
2,374
16,375
Acquisition related (benefits) costs
(494
)
-
(494
)
(40
)
Restructuring (benefits) costs
31
(3,510
)
4,594
64,289
Other non-recurring items (2)
2,454
1,909
9,960
1,909
Adjusted EBITDA
$
156,483
21.4
%
$
143,189
19.5
%
$
667,932
23.8
%
$
711,144
24.6
%
(1)
Excluded items identified in the
reconciliation schedule are tax effected by application of a
non-GAAP effective tax rate. The non-GAAP tax provision is adjusted
for items, the nature of which and/or tax jurisdiction requires the
application of a specific tax rate or treatment.
(2)
Incremental costs to comply with the
European Union's In Vitro Diagnostics Regulation ("IVDR") for
previously approved products.
(3)
Gain from the release of an escrow for the
sale of a division in 2020.
(4)
Amount excludes interest income received
in connection with legal settlements.
2023 Financial Outlook
Forecasted non-GAAP operating margin excludes 78 basis points
related to amortization of purchased intangibles. Forecasted
non-GAAP operating margin does not reflect future gains and charges
that are inherently difficult to predict and estimate due to their
unknown timing, effect and/or significance, such as foreign
currency fluctuations, future gains or losses associated with
certain legal matters, acquisitions and restructuring
activities.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230216005696/en/
Investor Contact: Edward Chung, Investor Relations
510-741-6104 ir@bio-rad.com
Media Contact: Anna Gralinska, Corporate Communications
510-741-6643 cc@bio-rad.com
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Oct 2023 to Oct 2024